Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

Market Cap	14.22B +24.3%
Revenue (ttm)	2.98B +6.2%
Net Income	937.93M -10.8%
EPS	2.91 -10.7%
Shares Out	322.32M
PE Ratio	15.16
Forward PE	n/a
Dividend	1.87 (4.24%)
Ex-Dividend Date	n/a

Volume	3,629,083
Average Volume	3,028,772
Open	43.85
Previous Close	44.11
Day's Range	42.69 - 44.08
52-Week Range	34.60 - 57.98
Beta	0.38
RSI	59.55
Earnings Date	Mar 13, 2026

About SHA:600211

Tibet Rhodiola Pharmaceutical Holding Co. manufactures pharmaceuticals in China and internationally. The company offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. It also provides capsules, biological preparations, granules, and film-coating agents for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthritis, colds, and other fields. The company was founded in 1999 and is based in Lhasa, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 596
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600211

Financial Performance

In 2025, SHA:600211's revenue was 2.98 billion, an increase of 6.23% compared to the previous year's 2.81 billion. Earnings were 937.93 million, a decrease of -10.78%.